# US IVD Contract Manufacturing Market

> US IVD Contract Manufacturing Market Research Report: Size, Share, Trend Analysis By Product Type (Reagents, Diagnostic Devices, Assay Kits, Consumables), By Technology (Molecular Diagnostics, Immunoassays, Clinical Chemistry, Microbiology), By End-user (Hospitals, Diagnostic Laboratories, Research Institutions, Home Care), and By Service Type (Manufacturing Services, Research and Development Services, Packaging Services) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 11.9%
- **2024:** $ 4,500 Million
- **2025:** $ 5,035.5 Million
- **2035:** $ 15,500 Million
- **Key Players:** Thermo Fisher Scientific (US), Roche Diagnostics (CH), Abbott Laboratories (US), Siemens Healthineers (DE), Danaher Corporation (US), Becton Dickinson and Company (US), bioMérieux (FR), Ortho Clinical Diagnostics (US), Hologic (US), PerkinElmer (US)

**Report ID:** MRFR/HC/51268-HCR · **Pages:** 200 · **Author:** Nidhi Mandole & Rahul Gotadki · **Last Updated:** February 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-ivd-contract-manufacturing-market-53029

---

## Market Summary

## **US IVD Contract Manufacturing Market Overview**

As per MRFR analysis, the US IVD Contract Manufacturing Market Size was estimated at 1.74 (USD Billion) in 2023. The US IVD Contract Manufacturing Market is expected to grow from 1.95 (USD Billion) in 2024 to 3.49 (USD Billion) by 2035. The US IVD Contract Manufacturing Market CAGR (growth rate) is expected to be around 5.411% during the forecast period (2025 - 2035).

**Key US IVD Contract Manufacturing Market Trends Highlighted**

The growing need for personalised medicine, regulatory changes, and technological improvements are driving a number of significant trends in the US IVD (In Vitro Diagnostic) Contract Manufacturing Market. The increasing focus on diagnostics as vital instruments for illness management and prevention, especially in light of the COVID-19 pandemic, is one major market driver.

As a result, there is now a strong ecosystem for IVD producers, with both the public and commercial sectors investing more in research and development. Furthermore, contract manufacturers must adjust to meet the growing demand for more advanced diagnostic tests due to the increased incidence of chronic diseases in the US.

Utilising automation and digital technology to increase manufacturing efficiency and shorten the time to market for novel diagnostic tests is one of the market's opportunities. Contract manufacturers can benefit from the need for compliance in product development and quality assurance procedures as regulatory agencies such as the FDA continue to update their rules for medical devices.

There is also a big chance to improve quality control and expedite processes by using artificial intelligence and data analytics into manufacturing processes. There has been a noticeable shift in recent years towards cooperation and partnerships between US academic institutions, biotech businesses, and IVD producers.

Smaller businesses with cutting-edge technology can launch their solutions faster thanks to this cooperative strategy, which also helps to speed up product development. Additionally, because keeping in-house production facilities is expensive, there is a shift towards outsourcing manufacturing skills.

Stakeholders in the US IVD Contract Manufacturing Market can strategically position themselves to meet changing client needs and spur growth in a competitive market by concentrating on these developing trends.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**US IVD Contract Manufacturing Market Drivers**

**Increasing Demand for Point-of-Care Testing**

The US IVD Contract Manufacturing Market is driven by the rising demand for point-of-care testing (POCT), which has significantly accelerated due to the need for rapid diagnostic solutions. According to the Centers for Disease Control and Prevention (CDC), point-of-care testing has seen an increase in adoption, particularly during the COVID-19 pandemic, where it was essential for immediate diagnostic results.

This considerable shift in testing methods signifies a growing preference, with the market for POCT estimated to reach substantial figures, highlighting an upward trend.

Prominent companies such as Abbott Laboratories and Roche Diagnostics are focusing heavily on the development and manufacture of advanced point-of-care diagnostics, thereby contributing to overall growth in the contract manufacturing sector within the US.

This rising demand is expected to bolster the US IVD Contract Manufacturing Market as healthcare providers seek efficient and effective testing solutions.

**Advancements in Technology and Automation**

Technological advancements and automation in the manufacturing processes are critical drivers for the US IVD Contract Manufacturing Market. The integration of cutting-edge technologies such as artificial intelligence and machine learning in diagnostic manufacturing has shown to enhance production efficiency and accuracy.

Data from the National Institute of Standards and Technology indicates that automation can increase production efficiency by up to 30%, facilitating higher output with reduced human error.

Leading firms, including Thermo Fisher Scientific and Siemens Healthineers, are investing in automation, making significant strides in upgrading their manufacturing capabilities. This results in improved turnaround times and cost-effectiveness that greatly encourage more companies to outsource manufacturing to contract manufacturers in the US.

**Emphasis on Regulatory Compliance and Quality Control**

The increasing complexity of regulations surrounding in-vitro diagnostics (IVD) is fostering growth in the US IVD Contract Manufacturing Market, as original equipment manufacturers (OEMs) look to contract manufacturers to ensure compliance.

The US Food and Drug Administration (FDA) imposes strict guidelines that require adherence to the quality management system in manufacturing processes. Companies such as Becton Dickinson and Company are proactively engaging with contract manufacturers to adhere to these regulations, which has resulted in more stringent quality control measures in the production of diagnostic devices.

Emphasizing quality and compliance not only mitigates risks associated with regulatory failures but also positions these organizations as competitive in a pressing market, ultimately resulting in increased contract manufacturing referrals.

**Growing Focus on Chronic Disease Management**

The surge in chronic diseases such as diabetes, cardiovascular diseases, and cancers in the US is a significant driver within the US IVD Contract Manufacturing Market. According to the American Heart Association, over 48% of adults in the United States have some form of cardiovascular disease.

This mounting prevalence drives demand for diagnostic tests that are crucial for early detection and ongoing management of these illnesses. Entities like Abbott Laboratories and Medtronic are developing innovative diagnostic solutions, which pushes the need for specialized manufacturing capabilities.

Consequently, contract manufacturers are increasingly engaged to produce advanced diagnostic devices tailored for chronic disease management, creating a positive outlook for the market growth in the US.

**US IVD Contract Manufacturing Market Segment Insights**

**IVD Contract Manufacturing Market Product Type Insights**

The US IVD Contract Manufacturing Market encompasses various product types, each playing a crucial role in the overall landscape of diagnostic testing and medical technology. Among these, reagents are vital as they facilitate the biochemical reactions necessary for diagnostic processes, establishing their significance in the overall market.

They are commonly used in a wide range of tests, including infectious diseases, immunology, and genetics, thus driving significant demand and innovation in this field. Diagnostic devices, another key product type, include instruments and systems utilized to perform tests for the detection and diagnosis of diseases.

Their technological advancement, such as the integration of artificial intelligence and automation, is reshaping how diagnostics are conducted, leading to more accurate and quicker results, which are paramount in today's healthcare environment.

Assay kits, designed for specific testing needs, are integral to laboratories and clinics, enabling efficient and reliable analysis of samples. Their importance lies in the capacity to deliver precise results, which can lead to timely and effective treatment plans.

The growing need for personalized medicine and advancements in biotechnology further bolsters the demand for specialized assay kits in the market. Meanwhile, consumables play an essential role as they encompass various single-use items required during the testing process, ensuring the efficiency and cleanliness of diagnostic workflows.

The ongoing developments in manufacturing processes of consumables, driven by the need for scalable production and quality assurance, highlight their importance in supporting the healthcare sector. Overall, the intricate interplay between these product types within the US IVD Contract Manufacturing Market highlights the continuous growth and evolution of diagnostic solutions.

The combined demand from hospitals, laboratories, and research institutions is indicative of the dynamic nature of the market, fueled by technological innovations and the rising need for effective diagnostics. As the industry progresses, the emphasis on quality, reliability, and speed among these product types will remain a focal point to meet the increasing healthcare demands across the United States.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**IVD Contract Manufacturing Market Technology Insights**

The Technology segment of the US IVD Contract Manufacturing Market plays a crucial role in the broader healthcare landscape, facilitating advancements in disease detection and monitoring. This segment encompasses various areas, including Molecular Diagnostics, Immunoassays, Clinical Chemistry, and Microbiology, which are essential for developing precise and timely diagnostic solutions.

Molecular Diagnostics is particularly significant as it leverages genetic and molecular information, driving innovations in personalized medicine and targeted therapies. Immunoassays dominate the market by offering rapid and accurate results for a range of diseases, significantly enhancing patient management.

Clinical Chemistry remains a cornerstone of routine laboratory testing, ensuring the availability of vital biochemical data that informs clinical decisions. Meanwhile, Microbiology serves a fundamental purpose in identifying infectious agents, which is essential for public health safety and effective treatment strategies.

This diverse Technology landscape contributes to the overall enhancement of diagnostic accuracy and accessibility, meeting the increasing demand for efficient and reliable testing solutions in the US.

Growth drivers in this space are bolstered by heightened awareness of preventive healthcare and significant investments in Research and Development, while challenges include regulatory hurdles and maintaining product quality.

**IVD Contract Manufacturing Market End-user Insights**

The End-user segment of the US IVD Contract Manufacturing Market encompasses a variety of key players, including Hospitals, Diagnostic Laboratories, Research Institutions, and Home Care settings. Hospitals are crucial as they often require continuous supply of in-vitro diagnostic products to ensure accurate patient care.

This segment is characterized by advanced technological infrastructure that demands high-quality manufacturing standards, making them a significant contributor to the overall market dynamics. Diagnostic Laboratories play a vital role, representing the core of testing services and often exhibiting a majority holding due to their need for diverse IVD solutions tailored for varied diseases.

Research Institutions are also integral, as they drive innovation and new product development, facilitating advancements in the diagnostic field which can lead to growth opportunities. In recent years, the Home Care segment has gained prominence, underscoring the trend toward at-home testing solutions, aligning with the growing consumer preference for convenience and remote health management.

Collectively, these segments reflect the diverse applications of IVD products, highlighting a dynamically evolving landscape driven by technological advancements and changing healthcare needs in the US.

**IVD Contract Manufacturing Market Service Type Insights**

The US IVD Contract Manufacturing Market focuses on various Service Type segments essential for producing in vitro diagnostic devices. Among these, Manufacturing Services encompass a wide range of processes, including assembly and quality control, which are critical for meeting strict regulatory standards in the US healthcare landscape.

Research and Development Services play a significant role by driving innovation and enhancing product efficacy through extensive testing and validation processes, aiding manufacturers in staying competitive. Packaging Services are crucial as they ensure product integrity, comply with regulatory requirements, and enhance marketability.

The growing demand for personalized medicine and increased prevalence of chronic diseases in the US are driving growth and investment in these service segments. Overall, the segmentation demonstrates an intricate interdependence among these services, with each contributing significantly to the overall efficiency, safety, and quality of IVD products in the market.

The engagement in technology advancements and focus on regulatory compliance are essential in maintaining market dynamics and addressing the challenges posed by ever-evolving healthcare demands.

**US IVD Contract Manufacturing Market Key Players and Competitive Insights**

The US IVD Contract Manufacturing Market has been experiencing dynamic changes, driven by advancements in technology, increasing demand for diagnostic tests, and a shift towards personalized medicine. The competitive landscape features numerous players who provide essential services from product development to regulatory compliance.

This sector is characterized by collaborations, joint ventures, and partnerships, as companies strive to enhance their capabilities and market reach. The growing prevalence of chronic diseases and a greater emphasis on preventive healthcare have further stimulated demand, creating opportunities for both established firms and new entrants.

The emergence of innovative diagnostic solutions and the push for rapid testing methods position this market at the forefront of healthcare strategy in the US.

Abbott Laboratories stands out in the US IVD Contract Manufacturing Market due to its vast expertise and solid brand reputation. The company leverages its extensive portfolio of diagnostic products, which include immunoassays, molecular diagnostics, and point-of-care testing solutions.

Abbott's strengths are exemplified by its robust research and development capabilities, allowing it to consistently introduce cutting-edge technologies that meet evolving healthcare needs. The company's established relationships with healthcare providers and its commitment to quality assurance further bolster its market presence.

By maintaining a strong focus on innovation and customer service, Abbott Laboratories reinforces its leadership position within the competitive frame of the US IVD sector, effectively addressing the increasing demand for efficient and reliable diagnostic solutions.

Thermo Fisher Scientific has a significant foothold in the US IVD Contract Manufacturing Market, recognized for its comprehensive array of laboratory and diagnostic solutions. The company specializes in various key products, including analyzers, reagents, and software services tailored for diagnostic applications.

With a focus on enhancing operational efficiencies and automating processes, Thermo Fisher fosters innovation in IVD manufacturing. Strengths such as extensive global reach, advanced technologies, and a wide service offering have positioned Thermo Fisher as a formidable player in the market.

The company's strategy involves strategic mergers and acquisitions to enhance its portfolio and expand market share. This proactive approach enables Thermo Fisher Scientific to stay ahead of the curve in a competitive landscape, ultimately driving growth and meeting the diverse needs of healthcare providers in the United States.

**Key Companies in the US IVD Contract Manufacturing Market Include:**

**US IVD Contract Manufacturing Market Developments**

The US IVD (In Vitro Diagnostic) Contract Manufacturing Market has recently seen significant developments. Notably, Abbott Laboratories and Danaher Corporation have reported substantial growth in their manufacturing capabilities, driven by rising demand for diagnostic testing amid ongoing public health challenges.

Siemens Healthineers launched a new production line to enhance its capacity for point-of-care testing, while Thermo Fisher Scientific has expanded its portfolio through strategic research initiatives. On the acquisition front, in March 2023, Roche Diagnostics announced the acquisition of a notable biosensor company to strengthen its market position, backed by consistent media coverage.

Additionally, Beckman Coulter has focused on increasing its automation in manufacturing to improve efficiency. The market has been buoyed by partnerships between IVD companies and technology providers to innovate new diagnostic solutions.

Major events in the last few years include the surge in testing requirements during the COVID-19 pandemic, leading to an uptick in manufacturing activities. Currently, the market shows positive valuation growth, driven by advancements in biotechnology and increasing healthcare investments, which support the continuous evolution of IVD contract manufacturing in the US.

**US Ivd Contract Manufacturing Market Segmentation Insights**

IVD Contract Manufacturing Market Product Type Outlook 

**IVD Contract Manufacturing Market Technology Outlook** 

**IVD Contract Manufacturing Market End-user Outlook** 

**IVD Contract Manufacturing Market Service Type Outlook**

## Market Drivers

### Focus on Cost Efficiency

Cost efficiency remains a pivotal driver in the IVD Contract-Manufacturing Market, as companies seek to optimize their operations. By outsourcing manufacturing processes, firms can significantly reduce overhead costs and allocate resources more effectively. This trend is particularly relevant in the context of rising production costs and the need for competitive pricing in the diagnostic sector. A recent analysis indicates that outsourcing can lead to cost savings of up to 30%, making it an attractive option for many companies. Consequently, the emphasis on cost efficiency is likely to propel the growth of the ivd contract-manufacturing market, as businesses prioritize financial sustainability.

### Regulatory Landscape Adaptation

The regulatory environment surrounding the IVD Contract-Manufacturing Market is continually evolving, necessitating adaptability from manufacturers. Compliance with stringent regulations set forth by agencies such as the FDA is essential for market participants. Companies that can navigate these complex regulatory frameworks effectively are better positioned to succeed. The increasing focus on quality assurance and risk management in manufacturing processes is indicative of this trend. As firms invest in compliance strategies, the overall integrity and reliability of the ivd contract-manufacturing market are enhanced, fostering trust among stakeholders and consumers alike.

### Innovation in Product Development

Innovation plays a crucial role in the IVD Contract-Manufacturing Market, as companies strive to develop advanced diagnostic solutions. The integration of cutting-edge technologies, such as artificial intelligence and machine learning, is transforming product development processes. These innovations not only improve the accuracy and speed of diagnostics but also reduce costs associated with manufacturing. As a result, companies are increasingly seeking contract manufacturers that can provide specialized expertise and state-of-the-art facilities. This trend is expected to drive growth in the ivd contract-manufacturing market, as firms look to leverage innovative solutions to stay competitive in a rapidly evolving landscape.

### Emergence of Personalized Medicine

The rise of personalized medicine is reshaping the landscape of the IVD Contract-Manufacturing Market. As healthcare shifts towards tailored treatment approaches, the demand for specific diagnostic tests that cater to individual patient needs is increasing. This trend necessitates the development of specialized manufacturing processes capable of producing customized diagnostic solutions. The market for personalized medicine is expected to grow significantly, with estimates suggesting a CAGR of over 10% in the coming years. This growth presents opportunities for contract manufacturers to expand their offerings and capabilities, thereby driving innovation and competitiveness within the ivd contract-manufacturing market.

### Rising Demand for Diagnostic Testing

The increasing prevalence of chronic diseases and the aging population in the US are driving the demand for diagnostic testing. This trend is particularly evident in the IVD Contract-Manufacturing Market, where the need for rapid and accurate testing solutions is paramount. According to recent data, the market for in vitro diagnostics is projected to reach approximately $30 billion by 2026, reflecting a compound annual growth rate (CAGR) of around 5%. This surge in demand necessitates robust contract manufacturing capabilities to meet the needs of diagnostic companies, thereby enhancing the overall efficiency and effectiveness of the ivd contract-manufacturing market.

## Future Outlook

The [IVD Contract Manufacturing Market](https://www.marketresearchfuture.com/reports/ivd-contract-manufacturing-market-22013) is projected to grow at 11.9% CAGR from 2025 to 2035, driven by technological advancements, increasing demand for diagnostics, and regulatory support.

**New opportunities:**

- Development of customized diagnostic kits for niche markets.
- Expansion of automation in manufacturing processes to enhance efficiency.
- Strategic partnerships with biotech firms for innovative product development.

By 2035, the market is expected to achieve substantial growth, positioning itself as a leader in the diagnostics sector.

## Segment Insights

### By Product Type: Reagents (Largest) vs. Diagnostic Devices (Fastest-Growing)

In the US ivd contract-manufacturing market, the distribution of market share among product types reveals that reagents lead significantly, capturing the largest portion. Diagnostic devices follow closely, showing an impressive and rapidly growing share. Assay kits and consumables represent smaller segments, yet they contribute meaningfully to the overall dynamics of the market. The competitive landscape underscores an increasing reliance on reagents, while diagnostic devices are gaining momentum as healthcare demands evolve.

The growth trends for these segments are fueled by technological advancements and increasing healthcare needs. Reagents are witnessing sustained demand due to their essential role in diagnostics. In contrast, diagnostic devices are emerging as the fastest-growing category, driven by innovations that enhance efficiency and accuracy in testing. The expansion of personalized medicine and point-of-care testing is further propelling growth across the segment, fostering an environment ripe for development.

Reagents (Dominant) vs. Assay Kits (Emerging)

Reagents play a dominant role in the US ivd contract-manufacturing market, characterized by their crucial applications in various diagnostic processes. They are essential for the preparation of test solutions and ensure accuracy in results. On the other hand, assay kits are an emerging segment, which has garnered attention due to the increasing demand for specific and efficient testing solutions. Assay kits encapsulate multiple components, including reagents and protocols, making them user-friendly. Their growth is spurred by advancements in assay technology and the emphasis on rapid diagnostic testing. Together, these segments highlight the dynamic nature of the market, with reagents holding a solid foundation and assay kits showcasing the potential for future expansion.

### By Technology: Molecular Diagnostics (Largest) vs. Immunoassays (Fastest-Growing)

In the US ivd contract-manufacturing market, Molecular Diagnostics holds a significant share, reflecting its critical role in disease detection and management. This segment's robust market presence is attributed to its advanced technologies and innovative solutions that enhance diagnostics precision. Immunoassays, while smaller in market share, exhibit rapid growth trends and increasing adoption across clinical settings, underlining their importance in various diagnostic applications.

The growth of Molecular Diagnostics is driven by the rising need for personalized medicine and point-of-care testing. Technological advancements, including next-generation sequencing and bioinformatics applications, further bolster this segment's expansion. Conversely, Immunoassays are becoming increasingly popular due to their versatility and adaptability in different laboratory settings, making them essential for multiple diagnostic purposes. Their growth is fueled by increasing investments in R&D and a surge in specialty testing methodologies that cater to specific health conditions.

Molecular Diagnostics (Dominant) vs. Immunoassays (Emerging)

Molecular Diagnostics serves as the dominant force within the technology segment of the US ivd contract-manufacturing market, characterized by its innovative techniques that allow for the comprehensive analysis of genetic material. This segment's strength lies in its ability to deliver precise results for various diseases, thereby improving patient outcomes. On the other hand, Immunoassays represent an emerging segment with a versatile application range; they can detect a variety of substances within biological samples. Their adaptability and quick turnaround time make them increasingly favorable in many diagnostic environments. Both segments emphasize technological advancements, yet Molecular Diagnostics leads in market dominance, while Immunoassays are gaining momentum as major contributors to overall market growth.

### By End User: Hospitals (Largest) vs. Diagnostic Laboratories (Fastest-Growing)

In the US ivd contract-manufacturing market, hospitals hold the largest share among the end user segments, significantly influencing the overall demand for diagnostic solutions. This sector capitalizes on the continuous influx of patients and the need for advanced medical diagnostics, which is crucial for patient care and management. Diagnostic laboratories, while smaller in market share, are rapidly gaining ground due to their pivotal role in disease detection and the increasing adoption of point-of-care testing technologies.

The growth trends for the end user segments reveal a dynamic shift, with diagnostic laboratories showcasing the fastest growth trajectory. This surge is driven by technological advancements and an emphasis on early diagnosis, which are increasingly benefiting lab environments. Simultaneously, hospitals continue to expand their service capacities, driven by rising patient volumes and the ongoing demand for integrated diagnostic services capable of enhancing clinical outcomes.

Hospitals (Dominant) vs. Research Institutions (Emerging)

Hospitals are regarded as the dominant end user in the US ivd contract-manufacturing market due to their extensive infrastructure, significant patient traffic, and comprehensive diagnostic requirements. They continually invest in innovative diagnostic solutions to improve patient outcomes. In contrast, research institutions represent an emerging segment, driven by the need for advanced research methodologies and novel diagnostics. Research institutions focus on developing cutting-edge technologies that can enhance testing accuracy and efficiency. This segment is characterized by a collaborative approach with manufacturers to innovate and adapt solutions that meet evolving scientific needs. As these institutions grow in prominence, they are expected to contribute significantly to the overall advancement of diagnostic capabilities.

### By Service Type: Manufacturing Services (Largest) vs. Research and Development Services (Fastest-Growing)

In the US ivd contract-manufacturing market, the distribution of market share among service types reveals that Manufacturing Services is the dominant segment, capturing a significant portion of the overall market. Research and Development Services follow closely, with a notable share, reflecting the increasing demand for innovative solutions. Packaging Services, while essential, commands a smaller market presence compared to the other two segments.

Growth trends in the US ivd contract-manufacturing market indicate that Research and Development Services is experiencing rapid expansion due to advancements in technology and increased investments in healthcare. The demand for personalized medicine and complex diagnostics is driving this growth, while Manufacturing Services remains a stronghold driven by established contracts and robust client relationships. Both segments are essential for the market's evolution, targeting distinct areas of need.

Manufacturing Services (Dominant) vs. Research and Development Services (Emerging)

Manufacturing Services stands as the dominant force in the US ivd contract-manufacturing market, characterized by its extensive capabilities in producing high-quality in vitro diagnostics products. This segment thrives on established processes and reliable supply chains, catering to a range of clients with diverse needs. On the other hand, Research and Development Services is emerging rapidly, fueled by the need for innovative solutions and advancements in medical technology. This segment focuses on developing cutting-edge diagnostics, which are increasingly essential to meet evolving healthcare demands. The interplay between these two segments creates a dynamic landscape where established manufacturing processes must adapt to emerging trends driven by research and innovation.

## Competitive Benchmarking

The IVD contract-manufacturing market exhibits a dynamic competitive landscape, characterized by rapid innovation and strategic collaborations among key players. Major companies such as Thermo Fisher Scientific (US), Abbott Laboratories (US), and Danaher Corporation (US) are at the forefront, leveraging their extensive portfolios and technological capabilities to enhance operational efficiencies. These firms focus on innovation and digital transformation, which appear to be pivotal in shaping their competitive positioning. The collective strategies of these companies suggest a trend towards integrated solutions that not only meet regulatory standards but also address the evolving needs of healthcare providers.Key business tactics within this market include localizing manufacturing and optimizing supply chains to enhance responsiveness and reduce costs. The competitive structure is moderately fragmented, with several players vying for market share, yet a few dominant firms hold substantial influence. This duality fosters an environment where innovation is crucial, as companies strive to differentiate themselves through advanced technologies and tailored services.

In September  Thermo Fisher Scientific (US) announced a strategic partnership with a leading biotechnology firm to co-develop next-generation diagnostic assays. This collaboration is expected to enhance their product offerings and expand their market reach, indicating a strong commitment to innovation and responsiveness to market demands. Such partnerships may significantly bolster their competitive edge by integrating cutting-edge technologies into their manufacturing processes.

In October  Abbott Laboratories (US) unveiled a new facility dedicated to the production of molecular diagnostics, aimed at increasing their manufacturing capacity by 30%. This expansion not only reflects Abbott's strategic focus on meeting rising demand but also underscores the importance of scalability in the current market. The facility is anticipated to enhance their operational efficiency and reduce lead times, thereby strengthening their position in the IVD contract-manufacturing sector.

In August  Danaher Corporation (US) completed the acquisition of a prominent diagnostics company, which is expected to enhance their technological capabilities and broaden their product portfolio. This acquisition aligns with Danaher’s strategy to integrate advanced technologies into their manufacturing processes, potentially leading to improved product quality and innovation. Such strategic moves indicate a trend towards consolidation in the market, as companies seek to enhance their competitive positioning through acquisitions.

As of November  the IVD contract-manufacturing market is increasingly defined by trends such as digitalization, sustainability, and the integration of artificial intelligence (AI) into manufacturing processes. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in driving innovation and enhancing supply chain reliability. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on technological advancements and sustainable practices, suggesting a transformative shift in how companies approach market challenges.

## Recent News & Developments

The US IVD (In Vitro Diagnostic) Contract Manufacturing Market has recently seen significant developments. Notably, Abbott Laboratories and Danaher Corporation have reported substantial growth in their manufacturing capabilities, driven by rising demand for diagnostic testing amid ongoing public health challenges.

Siemens Healthineers launched a new production line to enhance its capacity for point-of-care testing, while Thermo Fisher Scientific has expanded its portfolio through strategic research initiatives. On the acquisition front, in March 2023, Roche Diagnostics announced the acquisition of a notable biosensor company to strengthen its market position, backed by consistent media coverage.

Additionally, Beckman Coulter has focused on increasing its automation in manufacturing to improve efficiency. The market has been buoyed by partnerships between IVD companies and technology providers to innovate new diagnostic solutions.

Major events in the last few years include the surge in testing requirements during the COVID-19 pandemic, leading to an uptick in manufacturing activities. Currently, the market shows positive valuation growth, driven by advancements in biotechnology and increasing healthcare investments, which support the continuous evolution of IVD contract manufacturing in the US.

## Report Scope

| MARKET SIZE 2024 | 4500.0(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 5035.5(USD Million) |
| MARKET SIZE 2035 | 15500.0(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 11.9% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Thermo Fisher Scientific (US), Roche Diagnostics (CH), Abbott Laboratories (US), Siemens Healthineers (DE), Danaher Corporation (US), Becton Dickinson and Company (US), bioMérieux (FR), Ortho Clinical Diagnostics (US), Hologic (US), PerkinElmer (US) |
| Segments Covered | Product Type, Technology, End User, Service Type |
| Key Market Opportunities | Integration of advanced automation technologies enhances efficiency in the ivd contract-manufacturing market. |
| Key Market Dynamics | Rising demand for personalized medicine drives innovation and competition in the IVD contract-manufacturing market. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What is the current valuation of the US IVD contract-manufacturing market?**
A: The market valuation was $4500.0 Million in 2024.

**Q: What is the projected market size for the US IVD contract-manufacturing market by 2035?**
A: The market is projected to reach $15500.0 Million by 2035.

**Q: What is the expected CAGR for the US IVD contract-manufacturing market during the forecast period?**
A: The expected CAGR is 11.9% from 2025 to 2035.

**Q: Which product type segment holds the largest market share in the US IVD contract-manufacturing market?**
A: The Consumables segment was valued at $1900.0 Million in 2024 and is expected to grow significantly.

**Q: How do the revenues from diagnostic devices compare to those from assay kits in the US IVD contract-manufacturing market?**
A: In 2024, diagnostic devices generated $1500.0 Million, while assay kits contributed $1200.0 Million.

**Q: What are the key technology segments in the US IVD contract-manufacturing market?**
A: Key technology segments include Clinical Chemistry, valued at $1500.0 Million, and Immunoassays, valued at $1200.0 Million in 2024.

**Q: Which end-user segment is projected to experience the highest growth in the US IVD contract-manufacturing market?**
A: Diagnostic Laboratories, valued at $1800.0 Million in 2024, are likely to experience substantial growth.

**Q: What services are included in the US IVD contract-manufacturing market?**
A: The market includes Manufacturing Services, Research and Development Services, and Packaging Services.

**Q: Who are the leading players in the US IVD contract-manufacturing market?**
A: Key players include Thermo Fisher Scientific, Abbott Laboratories, and Siemens Healthineers.

**Q: What is the significance of the projected growth in the US IVD contract-manufacturing market?**
A: The projected growth indicates a robust demand for innovative diagnostic solutions and services.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-ivd-contract-manufacturing-market-53029*